193 related articles for article (PubMed ID: 27226777)
1. EphB4/ephrinB2 Contributes to Imatinib Resistance in Chronic Myeloid Leukemia Involved in Cytoskeletal Proteins.
Li L; Xu N; Zhang JF; Xu LL; Zhou X; Huang BT; Li YL; Liu XL
Int J Med Sci; 2016; 13(5):365-73. PubMed ID: 27226777
[TBL] [Abstract][Full Text] [Related]
2. Distinct EphB4-mediated mechanisms of apoptotic and resistance to dasatinib in human chronic myeloid leukemia and K562 cell lines.
Zhao WH; Huang BT; Zhang JY; Zeng QC
Leuk Res; 2017 Dec; 63():28-33. PubMed ID: 29096333
[TBL] [Abstract][Full Text] [Related]
3. EphB4-VAV1 signaling pathway is associated with imatinib resistance in chronic myeloid leukemia cells.
Zhang JF; Xu N; Du QF; Li R; Liu XL
Blood Cells Mol Dis; 2016 Jul; 59():58-62. PubMed ID: 27282569
[TBL] [Abstract][Full Text] [Related]
4. Homoharringtonine contributes to imatinib sensitivity by blocking the EphB4/RhoA pathway in chronic myeloid leukemia cell lines.
Huang BT; Zeng QC; Zhao WH; Tan Y
Med Oncol; 2014 Feb; 31(2):836. PubMed ID: 24415355
[TBL] [Abstract][Full Text] [Related]
5. Vandetanib drives growth arrest and promotes sensitivity to imatinib in chronic myeloid leukemia by targeting ephrin type-B receptor 4.
Ma W; Zhu M; Wang B; Gong Z; Du X; Yang T; Shi X; Dai B; Zhan Y; Zhang D; Ji Y; Wang Y; Li S; Zhang Y
Mol Oncol; 2022 Jul; 16(14):2747-2765. PubMed ID: 35689424
[TBL] [Abstract][Full Text] [Related]
6. Knock-down of CIAPIN1 sensitizes K562 chronic myeloid leukemia cells to Imatinib by regulation of cell cycle and apoptosis-associated members via NF-κB and ERK5 signaling pathway.
Wang J; Li Q; Wang C; Xiong Q; Lin Y; Sun Q; Jin H; Yang F; Ren X; Pang T
Biochem Pharmacol; 2016 Jan; 99():132-45. PubMed ID: 26679828
[TBL] [Abstract][Full Text] [Related]
7. BCR-ABL-independent and RAS / MAPK pathway-dependent form of imatinib resistance in Ph-positive acute lymphoblastic leukemia cell line with activation of EphB4.
Suzuki M; Abe A; Imagama S; Nomura Y; Tanizaki R; Minami Y; Hayakawa F; Ito Y; Katsumi A; Yamamoto K; Emi N; Kiyoi H; Naoe T
Eur J Haematol; 2010 Mar; 84(3):229-38. PubMed ID: 20002159
[TBL] [Abstract][Full Text] [Related]
8. The antiproliferation effect of berbamine on k562 resistant cells by inhibiting NF-kappaB pathway.
Wei YL; Liang Y; Xu L; Zhao XY
Anat Rec (Hoboken); 2009 Jul; 292(7):945-50. PubMed ID: 19548306
[TBL] [Abstract][Full Text] [Related]
9. HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation.
Kim SJ; Jung KH; Yan HH; Son MK; Fang Z; Ryu YL; Lee H; Lim JH; Suh JK; Kim J; Lee S; Hong S; Hong SS
Oncotarget; 2015 Jan; 6(3):1507-18. PubMed ID: 25483100
[TBL] [Abstract][Full Text] [Related]
10. Adiponectin signals through Adiponectin Receptor 1 to reverse imatinib resistance in K562 human chronic myeloid leukemia cells.
Wu S; Zheng C; Chen S; Lin B; Chen Y; Zhou W; Li Z
Biochem Biophys Res Commun; 2015 Jan; 456(1):367-72. PubMed ID: 25475722
[TBL] [Abstract][Full Text] [Related]
11. Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming.
Zhao F; Mancuso A; Bui TV; Tong X; Gruber JJ; Swider CR; Sanchez PV; Lum JJ; Sayed N; Melo JV; Perl AE; Carroll M; Tuttle SW; Thompson CB
Oncogene; 2010 May; 29(20):2962-72. PubMed ID: 20228846
[TBL] [Abstract][Full Text] [Related]
12. Computational and mechanistic studies on the effect of galactoxyloglucan: Imatinib nanoconjugate in imatinib resistant K562 cells.
James AR; Unnikrishnan BS; Priya R; Joseph MM; Manojkumar TK; Raveendran Pillai K; Shiji R; Preethi GU; Kusumakumary P; Sreelekha TT
Tumour Biol; 2017 Mar; 39(3):1010428317695946. PubMed ID: 28345463
[TBL] [Abstract][Full Text] [Related]
13. Bone marrow microenvironment confers imatinib resistance to chronic myelogenous leukemia and oroxylin A reverses the resistance by suppressing Stat3 pathway.
Li X; Miao H; Zhang Y; Li W; Li Z; Zhou Y; Zhao L; Guo Q
Arch Toxicol; 2015 Jan; 89(1):121-36. PubMed ID: 24671465
[TBL] [Abstract][Full Text] [Related]
14. Secretion of IL-1β from imatinib-resistant chronic myeloid leukemia cells contributes to BCR-ABL mutation-independent imatinib resistance.
Lee CR; Kang JA; Kim HE; Choi Y; Yang T; Park SG
FEBS Lett; 2016 Feb; 590(3):358-68. PubMed ID: 26831735
[TBL] [Abstract][Full Text] [Related]
15. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
[TBL] [Abstract][Full Text] [Related]
16. Establishment of a new Glivec-resistant chronic myeloid leukemia cell line, SNUCML-02, using an in vivo model.
Park J; Kim KI; Koh Y; Won NH; Oh JM; Lee DS; Kim BK; Ahn KS; Yoon SS
Exp Hematol; 2010 Sep; 38(9):773-81. PubMed ID: 20438801
[TBL] [Abstract][Full Text] [Related]
17. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.
Soverini S; Colarossi S; Gnani A; Rosti G; Castagnetti F; Poerio A; Iacobucci I; Amabile M; Abruzzese E; Orlandi E; Radaelli F; Ciccone F; Tiribelli M; di Lorenzo R; Caracciolo C; Izzo B; Pane F; Saglio G; Baccarani M; Martinelli G;
Clin Cancer Res; 2006 Dec; 12(24):7374-9. PubMed ID: 17189410
[TBL] [Abstract][Full Text] [Related]
18. The effects of ephrinB2 signaling on proliferation and invasion in glioblastoma multiforme.
Bhatia S; Bukkapatnam S; Van Court B; Phan A; Oweida A; Gadwa J; Mueller AC; Piper M; Darragh L; Nguyen D; Gilani A; Knitz M; Bickett T; Green A; Venkataraman S; Vibhakar R; Cittelly D; Karam SD
Mol Carcinog; 2020 Sep; 59(9):1064-1075. PubMed ID: 32567728
[TBL] [Abstract][Full Text] [Related]
19. EphrinB2-EphB4 signalling provides Rho-mediated homeostatic control of lymphatic endothelial cell junction integrity.
Frye M; Stritt S; Ortsäter H; Hernandez Vasquez M; Kaakinen M; Vicente A; Wiseman J; Eklund L; Martínez-Torrecuadrada JL; Vestweber D; Mäkinen T
Elife; 2020 Sep; 9():. PubMed ID: 32897857
[TBL] [Abstract][Full Text] [Related]
20. EphB4 promotes site-specific metastatic tumor cell dissemination by interacting with endothelial cell-expressed ephrinB2.
Héroult M; Schaffner F; Pfaff D; Prahst C; Kirmse R; Kutschera S; Riedel M; Ludwig T; Vajkoczy P; Graeser R; Augustin HG
Mol Cancer Res; 2010 Oct; 8(10):1297-309. PubMed ID: 21047731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
